Amplitude Ventures

Congratulations to our portfolio company Thryv Therapeutics Inc. on their announcement today of positive top-line results from their Wave I Part 2 study in Long QT Syndrome Type 2 & 3 patients. See below for more information #Biotech #VentureCapital #Healthcare #LQTSyndrome #AmplitudeVC

Amplitude Ventures portfolio company Thryv Therapeutics Inc., a clinical stage biotech company dedicated to developing treatments for rare and life-threatening cardiovascular indications, announced this week that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation to LQT-1213 for the treatment of Long QT Syndrome (LQTS).  LQT-1213 is a novel, first-in-class SGK1 inhibitor specifically designed to treat congenital LQTS. Thryv has developed a series of SGK1 inhibitors for the treatment of cardiometabolic stress associated with various arrhythmic diseases including LQTS, atrial fibrillation, and heart failure. Read the full press release here: https://lnkd.in/eK543jih #OrphanDrugDesignation #LQTS #OrphanDrug #RareDiseaseAwareness #Biotech #Healthcare #AmplitudeVC

Today we are pleased to announce our investment in Nomic Bio's $42M oversubscribed Series B round. Congratulations to Milad Dagher, Jeff Munzar and the rest of the Nomic team on creating a next-generation proteomics company. We believe proteomics is the future of life sciences, similar to what genomics brought to the world in the 2000s/2010s. We're happy to partner with Nomic on their path to scaling and commercializing their nELISA platform, which aims to make proteomics accessible for more scientists, drug developers and entrepreneurs to improve patient lives. For more thoughts on the company, please see our blog post below https://lnkd.in/gjNUF8bU #Proteomics #LifeSciences #VentureCapital #Healthcare #AmplitudeVC

We are thrilled to announce today Radiant Biotherapeutics $35M Series A financing. They'll be adding key members to the team, and accelerating the advance of their lead clinical candidate, 4-1BB, towards clinical trials. Thanks to the investors who joined us including the Bill & Melinda Gates Foundation, BDC, abrdn Investment Trusts and the existing investors at FACIT, Alexandria Real Estate Equities, Inc. and TIAP - Toronto Innovation Acceleration Partners. Since the beginning, Amplitude Ventures saw the potential of the Multabody™ platform, which creates a new class of biologics with an unprecedented combination of multivalency, which results in greater avidity or powerful grip on targets and multi-specificity. Multabodies do things that other existing and developmental antibody treatments can’t do, and that’s why we’re excited to help the company bring this powerful new tool to the fight against difficult, heterogeneous diseases. Congratulations to Art Fratamico, Jo Hulme and the rest of the Radiant team on this exciting announcement. For more of our thoughts on the company, please see below https://lnkd.in/g9Umk5xR #Radiant #Multabody #Antibodies #AmplitudeVC #Biotech #VentureCapital

We're thrilled to announce another addition to our portfolio. Led by Ali Tehrani, David Poon and Candice Madalena, DCx Biotherapeutics Corporation was founded with Amplitude Ventures to develop 1st-in-class next generation antibody-drug conjugates that are more efficacious and better tolerated than traditional anti-mitotic or topoisomerase inhibiting ADCs. Congratulations to the #DCx team on getting this started. Follow DCx Biotherapeutics Corporation for more information in the coming months

Congratulations to our portfolio company Prilenia on their announcement today of the acceptance of their European Marketing Authorization (MAA) application for Pridopidine for the treatment of adults with Huntington's Disease. Congrats to Dr. Michael Hayden MBChB , PhD, Limor Ben Har, Henk Schuring and the rest of the Prilenia team on getting this medicine closer to patients.

We wanted to congratulate Congruence Therapeutics and their CEO Clarissa Desjardins who was recently selected for BIOTECanada's 'Game-Changing Industry Leadership Award.' The “Game-Changing Industry Leadership Award” recognizes an individual who has exhibited unparalleled vision and leadership in the Canadian biotechnology sector, with a significant impact on a global scale. This award celebrates visionary leaders who have not only contributed to the advancement of biotechnology in Canada but have also set new benchmarks for excellence across the industry. Congratulations Clarissa!

Not to be missed!

We are thrilled to announce our investment into Amplitude Ventures Fund II to give early stage Alberta health and life science startups the continuing opportunity to access Amplitude’s specialized precision medicine expertise and investment. Amplitude is also establishing a full-time presence in Alberta with a new investor Nadia Lachman. “Alberta life science startups require access to capital and expertise from specialized life science investors in order to scale,” commented Kristina Williams, CEO, Alberta Enterprise Corporation. “Amplitude contributes deep expertise to help Alberta entrepreneurs building new precision medicine companies which can drive meaningful outcomes in human health and transform the future of healthcare.”

We are thrilled to welcome Nadia Lachman to the Amplitude Ventures team. Nadia is based in Calgary and will be working with and supporting the entire Amplitude team and portfolio. Her passion for supporting life-changing innovation is strong and we are pleased to enable her to direct her passion and energy with the Amplitude platform as we build the next generation of great companies.   With our recently closed $263M Amplitude Fund II, we are actively looking for new investments in Precision Medicine at the intersection of AI/ML and biology, and recently closed our 5th investment in the new fund. Welcome aboard Nadia – lots to come!